<DOC>
	<DOCNO>NCT02168543</DOCNO>
	<brief_summary>- Locally deliver Alendronate ( ALN ) potent inhibitory effect bone increase new bone formation chronic periodontitis patient - Till date study report effect local delivery ALN chronic periodontitis patient among smoker . Hence aim study investigate clinical radiographic effect locally deliver ALN adjunct non surgical treatment smoker chronic periodontitis patient .</brief_summary>
	<brief_title>1 % Alendronate Gel Treatment Chronic Periodontitis Among Smokers</brief_title>
	<detailed_description />
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Chronic Periodontitis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Systemically healthy subject probe depth ( PD ) ≥ 5 mm periodontal attachment level ( PAL ) ≥ 4 6 mm radiographical vertical bone loss ≥ 3 mm No history periodontal therapy precede last 6 month No use antibiotic precede 6 month Subjects know systemic disease Known suspect allergy ALN/bisphosphonate group Those systemic ALN/bisphosphonate therapy Subjects aggressive periodontitis , Use smokeless tobacco form , Alcoholics Immunocompromised subject Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>